Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07763327
Effects of a Wearable Device ,Phone App and Exercise on Cervico-thoracic Posture in University Students.Riphah International UniversityNot Yet RecruitingNot Applicable
NCT07763327Not Yet Recruiting
Not Applicable
Effects of a Wearable Device ,Phone App and Exercise on Cervico-thoracic Posture...Riphah International Univ...
NCT07762768
Effect of CSIR-Developed High-Protein, Low-Glycaemic Index Rice on Glycaemic Response in Individuals With PrediabetesCSIR National Institute for Interdisciplinary Science and Technology (NIIST), ThiruvananthapuramNot Yet RecruitingNot Applicable
NCT07762768Not Yet Recruiting
Not Applicable
Effect of CSIR-Developed High-Protein, Low-Glycaemic Index Rice on Glycaemic Res...CSIR National Institute f...
NCT07763587
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Benefit Evaluation of Acupuncture Collaborative Management RegimenFirst Teaching Hospital of Tianjin University of Traditional Chinese MedicineNot Yet RecruitingNot Applicable
NCT07763587Not Yet Recruiting
Not Applicable
Analysis of Multimodal Psychosomatic Comorbidity Burden in Breast Cancer and Ben...First Teaching Hospital o...
NCT07763964
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 100 mg/1000 mg in Healthy Subjects, Fed Study.ADIUMCompletedNot Applicable
NCT07763964Completed
Not Applicable
Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitag...ADIUM
NCT07762794
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real World Setting in Patients With Extremity Arterial Injury Requiring Urgent RepairHumacyte, Inc.Not Yet RecruitingPhase 4
NCT07762794Not Yet Recruiting
Phase 4
Multicenter Study to Evaluate the Safety and Efficacy of SYMVESS™ in a Real Worl...Humacyte, Inc.
NCT07762638
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated in Study ID-069A302Idorsia Pharmaceuticals Ltd.Unknown
NCT07762638Unknown
—
Post Trial Access to Lucerastat for Patients With Fabry Disease Who Participated...Idorsia Pharmaceuticals L...
NCT07762924
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryFudan UniversityRecruitingPhase 2
NCT07762924Recruiting
Phase 2
Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Fol...Fudan University
NCT07764328
This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Balance in Women Who Suffer From Self-reported PCOS Symptoms.Mila Mend Inc.RecruitingNot Applicable
NCT07764328Recruiting
Not Applicable
This Study Aims to Evaluate Whether Milamend's Product Could Improve Hormone Bal...Mila Mend Inc.
NCT07763145
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy: A Randomized Control TrialHayatabad Medical ComplexNot Yet RecruitingNot Applicable
NCT07763145Not Yet Recruiting
Not Applicable
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resisti...Hayatabad Medical Complex
NCT07762274
The RenAtt Method for Diagnosing and Treating Attention Problems After Stroke and Brain Injury, Further Validation of RehAtt® DiSTRO Assessment of Cognitive and Visual FunctionDepartment of clinical sciences at Danderyd hospitalCompleted
NCT07762274Completed
—
The RenAtt Method for Diagnosing and Treating Attention Problems After Stroke an...Department of clinical sc...
NCT07762313
An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular Conduit in Adolescents With Extremity Arterial Injury.Humacyte, Inc.Not Yet RecruitingPhase 3
NCT07762313Not Yet Recruiting
Phase 3
An Open-label Study to Assess the Safety and Efficacy of SYMVESS® as a Vascular...Humacyte, Inc.
NCT07762001
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MDActive Not RecruitingPhase 1
NCT07762001Active Not Recruiting
Phase 1
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MD
NCT07763405
Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic StrokeThe First Affiliated Hospital of Nanchang UniversityNot Yet RecruitingPhase 4
NCT07763405Not Yet Recruiting
Phase 4
Lumbrokinase vs Placebo in Moderate-to-Severe Ischemic StrokeThe First Affiliated Hosp...
NCT07764250
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training in Elderly With Mild and Moderate Cognitive ImpairmentShifa Tameer-e-Millat UniversityRecruitingNot Applicable
NCT07764250Recruiting
Not Applicable
Comparative Evaluation of Immediate vs Progressive Standing Dual Task Training i...Shifa Tameer-e-Millat Uni...
NCT07762950
Blood Biomarkers and Gut Microbiota for Pancreatic Cancer Risk in Chronic PancreatitisChanghai HospitalNot Yet Recruiting
NCT07762950Not Yet Recruiting
—
Blood Biomarkers and Gut Microbiota for Pancreatic Cancer Risk in Chronic Pancre...Changhai Hospital
NCT07762365
Brain Stimulation Paired With Structured Reading Instruction in Children With DyslexiaGeneral Neuro Inc.RecruitingNot Applicable
NCT07762365Recruiting
Not Applicable
Brain Stimulation Paired With Structured Reading Instruction in Children With Dy...General Neuro Inc.
NCT07762144
Clinical Cohort Construction Program of Peking University Third HospitalPeking University Third HospitalEnrolling By Invitation
NCT07762144Enrolling By Invitation
—
Clinical Cohort Construction Program of Peking University Third HospitalPeking University Third H...
NCT07762781
Impact of a Mobile Exercise Application on Sleep, Pain, and Fitness in Healthy AdultsTokat Gaziosmanpasa UniversityCompletedNot Applicable
NCT07762781Completed
Not Applicable
Impact of a Mobile Exercise Application on Sleep, Pain, and Fitness in Healthy A...Tokat Gaziosmanpasa Unive...
Result Breakdown
Not yet recruiting10 (50%)
Recruiting4 (20%)
Completed3 (15%)
Unknown1 (5%)
Active, not recruiting1 (5%)
Enrolling by invitation1 (5%)
not_applicable9 (45%)
Not Specified5 (25%)
Phase 42 (10%)
Phase 22 (10%)
Phase 31 (5%)
Phase 11 (5%)